Literature DB >> 3356357

Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.

H Humphreys1, S Bourke, C Dooley, D McKenna, B Power, C T Keane, E C Sweeney, C O'Moráin.   

Abstract

This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3356357      PMCID： PMC1433591          DOI： 10.1136/gut.29.3.279

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  24 in total

1.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

2.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

3.  Spiral organisms in endoscopic biopsies of the human stomach.

Authors:  T P Rollason; J Stone; J M Rhodes
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

4.  Surface morphology of the gastroduodenal mucosa in duodenal ulceration.

Authors:  H W Steer
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

5.  Campylobacter like organisms on the gastric mucosa: culture, histological, and serological studies.

Authors:  D M Jones; A M Lessells; J Eldridge
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  The antrum in patients with duodenal and gastric ulcers.

Authors:  J Schrager; R Spink; S Mitra
Journal:  Gut       Date:  1967-10       Impact factor: 23.059

7.  Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

8.  Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer.

Authors:  G Vantrappen; P Rutgeerts; L Broeckaert; J Janssens
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

9.  Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro.

Authors:  R L Soutar; S B Coghill
Journal:  Gastroenterology       Date:  1986-07       Impact factor: 22.682

10.  Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate.

Authors:  D F Martin; D Hollanders; S J May; M M Ravenscroft; D E Tweedle; J P Miller
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321
View more
  22 in total

Review 1.  Helicobacter pylori.

Authors:  B Drumm
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

2.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

Authors:  A E Simor; S Ferro; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection.

Authors:  Yuichi Sato; Mitsuya Iwafuchi; Jun-Ichi Ueki; Akira Yoshimura; Tsutomu Mochizuki; Hirotaka Motoyama; Kazuhito Sugimura; Terasu Honma; Rintaro Narisawa; Takafumi Ichida; Hitoshi Asakura; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 6.  Helicobacter pylori in gastroduodenal disease.

Authors:  R J Loffeld
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

Review 7.  Campylobacter pylori and gastroduodenal disease.

Authors:  G E Buck
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  H. pylori-negative duodenal ulcer prevalence and causes in 774 patients.

Authors:  J P Gisbert; M Blanco; J M Mateos; L Fernández-Salazar; M Fernández-Bermejo; J Cantero; J M Pajares
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

9.  Imprint cytology--a cheap, rapid and effective method for diagnosing Helicobacter pylori.

Authors:  S P Misra; M Dwivedi; V Misra; S C Gupta
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

10.  Local gastric and serum amoxicillin concentrations after different oral application forms.

Authors:  M P Cooreman; P Krausgrill; K J Hengels
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.